A minimal-intervention clinical trial is a clinical trial within the meaning of Regulation (EU) No 536/2014 that meets all legally defined requirements for only minimal additional risk or minimal additional burden. It remains subject to authorisation and does not become an observational study. This special category reflects the fact that authorised medicinal products are investigated under narrowly defined conditions close to normal clinical practice.
Requirements and scope
The requirements are cumulative. The investigational medicinal products, with the exception of placebo, must be authorised. According to the protocol, they are used either in accordance with the conditions of the marketing authorisation, or their use is evidence-based and supported in each concerned Member State by published scientific evidence on safety and efficacy. In addition, compared with normal clinical practice, the diagnostic or monitoring procedures may cause only minimal additional risk or minimal additional burden for participants.
This category is not a blanket simplification for every study involving a known medicinal product. Even with an authorised product, dose, combination, indication, additional interventions or close monitoring may mean that a requirement is not met. The rationale must therefore be clearly set out in the application documents. The sponsor must assess normal clinical practice and the additional burden across all concerned Member States, not only the processes at a single site.
Conduct and documentation
The Regulation provides for less stringent rules for minimal-intervention clinical trials with regard to monitoring, requirements for the content of the Trial Master File, and traceability. This risk-proportionate approach does not change the consent requirements or the responsibility for quality and participant protection. The protocol, risk assessment, monitoring plan and medicinal product processes must practically support the chosen classification. If the requirements cease to be met during the course of the trial, the regulatory and operational impact must be assessed.
The classification should be completed before site activation begins. It influences the information in the protocol, the selection of critical data and processes, and the training of the teams involved. Operationally, it is particularly important to avoid retrospectively classifying additional diagnostics or monitoring as minor when they in fact represent a relevant additional burden for participants.
Distinction
Non-interventional studies are explicitly not covered by the Regulation. In such studies, the treatment decision is not predetermined by a trial protocol, and the use of the medicinal product follows routine practice only. By contrast, a minimal-intervention clinical trial is an interventional clinical trial applied for and authorised under the Regulation.
Compared with a regular clinical trial, it is not a different research logic but a legally defined risk category. If even one of the cumulative requirements is not met, it is not a minimal-intervention trial but a regular clinical trial. Terms such as observational study and pragmatic trial describe different perspectives and do not replace this legal assessment.
The classification must primarily reflect the additional procedures actually planned. This includes comparing trial procedures with standard care: Which examinations, contacts, blood draws, imaging, monitoring intervals or documentation requirements are added solely because of the trial? The answer may differ by Member State if marketing authorisations or clinical practice differ. A blanket reference to a known substance class is therefore not sufficient. The rationale should also explain how deviations from routine practice will be handled, particularly for use outside the conditions of the marketing authorisation. During conduct, it must be monitored whether additional burdens differ from what was planned. If relevant changes arise, the risk classification, monitoring and, where applicable, the regulatory documentation must be reviewed again. This ensures that the lower level of intervention remains a robust decision, not merely a formal one.
The decision must be documented transparently and reviewed in light of relevant changes. This enables the sponsor to explain to ethics committees and authorities why the category was chosen and whether the requirements continue to be met throughout the entire conduct. This ongoing review prevents the risk-proportionate classification from being applied purely formally.
Related terms such as non-interventional study, observational study and pragmatic trial must not override the legal classification. They may describe a similar care setting or a particular design, but they do not answer the three requirements of a minimal-intervention clinical trial.
Relevance for clinical trials
This three-way distinction is essential for the application, insurance, medicinal product management, monitoring and informed consent. An overly generous classification can lead to inappropriate dossier assumptions and later queries; a well-substantiated classification, by contrast, helps align effort with the actual additional risk. Especially for off-label but evidence-supported use, the scientific evidence and the additional procedures should be brought together early.
Full-service CROs such as Mediconomics support the classification analysis, preparation of the application dossier and the risk assessment. They align monitoring, medicinal product logistics, trial documentation and project management with the requirements of a minimal-intervention clinical trial and document the rationale for authorities and the ethics committee.
Frequently Asked Questions (FAQ)
Is a marketing authorisation for the medicinal product sufficient?
No. In addition to marketing authorisation, the protocol-defined use and the minimal additional risk or minimal additional burden must meet the other requirements.
Is a minimal-intervention trial an observational study?
No. It is an interventional clinical trial under the Regulation and is subject to the corresponding application procedure.
May additional examinations be performed?
Yes, provided that, compared with normal clinical practice, they cause only minimal additional risk or minimal additional burden.
Regulatory References
- Regulation (EU) No 536/2014, Article 2(2)(3) — defines the cumulative requirements.
- Regulation (EU) No 536/2014, Recital 11 — explains the risk-proportionate approach for this category.
- European Commission guidance on Regulation (EU) No 536/2014 — supports practical classification.
